Related Experiment Video
Updated: May 13, 2026
Rat Mesentery Angiogenesis Assay
Published on: June 18, 2011
Drug testing with angiogenesis models
1Sahlgrenska University Hospital, Department of Pathology, SE-413 45 Gothenburg, Sweden +46 31 342 19 54 ; +46 31 82 71 94 ; klas.norrby@pathology.gu.se.
Background:
The possibility to treat cancers and several angiogenesis- dependent diseases with non-toxic, antiangiogenic agents has revolutionized the therapeutic capabilities in the fields of oncology and ophthalmology, whereas therapeutic angiogenesis, governed by angiogenesis stimulators, is about to enter clinical medicine.
Objective:
To describe and critically evaluate the advantages and limitations of the most important and most frequently used preclinical in vivo angiogenesis assays as well as to appraise the preclinical models that are most widely used for studying antiangiogenic effects in tumors.
Methods:
Up-to-date literature survey.
Results/Conclusion:
Only few angiogenesis and tumor models appear to meet realistic standards fully in terms of biological relevance. Improvement of the biological pertinence and sensitivity of such models would apparently facilitate the translatability of preclinical data into clinical practice.
Insights
Preclinical models for studying antiangiogenic effects are crucial for cancer and ophthalmology treatments. Current in vivo angiogenesis assays require improvement for better clinical translation of anti-cancer therapies.
Area of Science:
- Oncology
- Ophthalmology
- Angiogenesis Research
Background:
- Antiangiogenic agents offer revolutionary treatments for cancers and angiogenesis-dependent diseases.
- Therapeutic angiogenesis, utilizing stimulators, is emerging in clinical applications.
Purpose of the Study:
- Critically evaluate preclinical in vivo angiogenesis assays.
- Appraise widely used preclinical models for studying antiangiogenic effects in tumors.
Main Methods:
- Conducted an up-to-date literature survey.
Main Results:
- Few angiogenesis and tumor models fully meet realistic standards for biological relevance.
- Existing models show limitations in accurately predicting clinical outcomes.
Conclusions:
- Enhancing the biological relevance and sensitivity of preclinical models is essential.
- Improved models will facilitate the translation of preclinical data into clinical practice for anti-cancer therapies.
Related Concept Videos
01:10Mechanism of Angiogenesis
01:24Regulation of Angiogenesis and Blood Supply